Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative
Monte Rosa Therapeutics posted a Q3 2025 loss of US$0.33 EPS and US$27.1 million net income loss, despite a trailing twelve-month profit of US$20.9 million. The company’s revenue has been volatile, from US$84.9 million in Q1 2025 to US$12.8 million in Q3 2025, which complicates the bullish narrative of 44.3% annual revenue growth. With a high P/E of 60.6x compared to peers and a forecast 3.3% annual EPS decline, investors face tension between current valuations and long-term profitability prospects.